Revenue increase driven primarily by Sanofi collaboration, including a $10.0 million milestone for an immunology small molecule program R&D expense decreased mainly due to non-recurrence of $22.8 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results